CONTEXT: Sentinel lymph node biopsy offers the potential for a less invasive means of assessing nodal involvement in breast cancer, compared with conventional axillary lymph node dissection.
A way to identify sentinel nodes that is more precise than gadolinium-enhanced MR is needed, however. At the International Society for Magnetic Resonance in Medicine conference in Kyoto, Japan, investigators from the National Cancer Institute reported encouraging results in a mouse experiment using a nano-sized dendrimer contrast agent to image lymphatic drainage in breast cancer.
RESULTS: The nano-sized polyamidoamine G6 dendrimer contrast agent (G6) was compared with conventional gadolinium-DTPA contrast material for evaluating lymph nodes and lymphatic drainage in normal mice and transgenic mice that develop spontaneous breast cancers. In the tumor-bearing mice, lymphatic flow from breast tumors to metastatic lymph nodes was readily visualized by means of dynamic micro-MR mammolymphangiography (dmMRML) using the nano-sized G6 contrast agent. On MR assessment, nodes containing solid tumor demonstrated filling defects or rim enhancement, allowing detection and diagnosis of micrometastasis. In normal mice, dmMRML visualized the axillary lymph node and its draining lymphatics at the initial time point. Two other lymph nodes (lateral thoracic and superficial cervical) and their draining lymphatics were also visualized. Lymphatic drainage was not seen when the researchers used gadolinium contrast, according to NCI staff scientist Dr. Histaka Kobayashi!.
IMAGES: Draining lymphatic vessels and lymph nodes from left breast tissue in a normal mouse are clearly depicted in Figure 1 on a dynamic 3D image acquired 30 minutes after G6 nano-sized contrast injection. Figure 2 shows a schema of that morphology. In Figure 3, fused surface and volume-rendered images of 3D dmMRML of a normal mouse show both the skin and the draining lymphatic system of the left breast.
IMPLICATIONS: Superior temporal and spatial resolution of the dmMRML technique should have applicability to the study of lymph nodes and lymphatic vessels in a variety of tumor types. The next step in the evaluation of the technique will likely focus on melanoma, Kobayashi said.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.